基于大型商业实验室残余血清估算丙型肝炎患病率与病毒清除率
估算HCV抗体阳性率为2.9%(95%CI 2.8%-3.0%),约6 887 000人曾感染;年轻成人病毒清除率(63.8%)低于年长成人(81.1%),提示消除工作仍需加强。
要点
- 年轻成人病毒清除率63.8%,低于年长成人的81.1%。
核心结论
- 尽管存在选择偏倚限制外推,治愈性治疗可及十年后负担仍显著,需全国协同推进丙肝消除。
研究设计与样本
- 横断面研究,覆盖美国50州及哥伦比亚特区,采用便利抽样获取常规临床残余血清标本n=81 483。
- 先测HCV抗体,阳性或不确定结果反射检测HCV RNA,并按美国年龄-性别分布进行嵌套耙平加权。
主要发现
- 18-≤75岁成人HCV抗体阳性率2.9%(95%CI 2.8%-3.0%),对应6 887 000人(95%CI 6 622 000-7 166 000)曾感染。
- 病毒清除率在年轻成人中为63.8%(95%CI 60.6%-66.9%),低于年长成人的81.1%(95%CI 78.9%-83.3%)。
临床怎么用
- 残余血清反射RNA检测可用于人群HCV感染负担与病毒清除情况的估算监测。
- 年轻成人病毒清除率偏低,提示该人群诊断与治疗衔接仍需加强。
- 估算结果可为国家及地区丙肝消除项目提供负担基线参考。
局限性
- 便利抽样与残余血清来源存在选择偏倚,限制结果对美国一般人群的外推。
- 原文未报告便利样本的招募细节与应答情况。
- 原文未报告不同州或地区层面的分层估算结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatitis C is a public health threat with national elimination targets, yet prevalence is challenging to measure. We utilized a novel approach to estimate hepatitis C prevalence among adults using residual sera from a large commercial laboratory. METHODS: We conducted a cross-sectional study in 50 states and the District of Columbia using a convenience sample of residual serum specimens (n = 81 483) among routine clinical specimens from adults aged 18-≤75 years. We randomly sampled within 2 age groups (18-≤49 years and 50-≤75 years) during November 2023-September 2024. Specimens were tested for hepatitis C virus (HCV) antibodies; reactive or equivocal results were reflexed to HCV ribonucleic acid (RNA) testing. We performed nested raking on the age-sex distribution of the United States. RESULTS: Among adults aged 18-≤75 years, we estimated that the HCV antibody prevalence was 2.9% (95% CI, 2.8%-3.0%), corresponding to 6 887 000 (95% CI, 6 622 000-7 166 000) persons ever infected, and the HCV RNA prevalence was 0.7% (95% CI, .7%-.8%), corresponding to 1 698 000 (95% CI, 1 554 000-1 845 000) persons currently infected. Viral clearance was lower among younger adults (63.8% [95% CI, 60.6%-66.9%]) than older adults (81.1% [95% CI, 78.9%-83.3%]). CONCLUSIONS: In this analysis of residual sera from a commercial laboratory, we estimated that approximately 1.70 million adults were diagnosed with HCV infection during November 2023-September 2024. Although underlying selection bias limits generalizability to the US population, the substantial burden estimated after a decade of available curative treatment underscores the need for concerted nationwide hepatitis C elimination efforts.
引用
- Hofmeister MG, Symum H, Swanson BE, et al. Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023-September 2024. Clin Infect Dis. 2026. PMID: 41502122. doi:10.1093/cid/ciag007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。